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16RESEARCH Open AccessOutcome and patterns of failure after
postoperative intensity modulated radiotherapy
for locally advanced or high-risk oral cavity
squamous cell carcinoma
Andreas Geretschläger1, Beat Bojaxhiu1, Susanne Crowe2, Andreas Arnold3, Peter Manser1, Wock Hallermann4,
Daniel M Aebersold1 and Pirus Ghadjar1*Abstract
Background: To determine the outcome and patterns of failure in oral cavity cancer (OCC) patients after
postoperative intensity modulated radiotherapy (IMRT) with concomitant systemic therapy.
Methods: All patients with locally advanced (AJCC stage III/IV) or high-risk OCC (AJCC stage II) who underwent
postoperative IMRT at our institution between December 2006 and July 2010 were retrospectively analyzed. The
primary endpoint was locoregional recurrence-free survival (LRRFS). Secondary endpoints included distant
metastasis-free survival (DMFS), overall survival (OS), acute and late toxicities.
Results: Overall 53 patients were analyzed. Twenty-three patients (43%) underwent concomitant chemotherapy
with cisplatin, two patients with carboplatin (4%) and four patients were treated with the monoclonal antibody
cetuximab (8%).
At a median follow-up of 2.3 (range, 1.1–4.6) years the 3-year LRRFS, DMFS and OS estimates were 79%, 90%, and
73% respectively. Twelve patients experienced a locoregional recurrence. Eight patients, 5 of which had both a flap
reconstruction and extracapsular extension (ECE), showed an unusual multifocal pattern of recurrence. Ten
locoregional recurrences occurred marginally or outside of the high-risk target volumes. Acute toxicity grades of 2
(27%) and 3 (66%) and late toxicity grades of 2 (34%) and 3 (11%) were observed.
Conclusion: LRRFS after postoperative IMRT is satisfying and toxicity is acceptable. The majority of locoregional
recurrences occurred marginally or outside of the high-risk target volumes. Improvement of high-risk target volume
definition especially in patients with flap reconstruction and ECE might transfer into better locoregional control.
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Treatment of locally advanced or high-risk oral cavity
cancer (OCC) involves extensive surgical procedures,
often combined with flap reconstruction, followed by
postoperative radiotherapy (RT) with systemic therapy if
certain risk factors are present. Postoperative RT as com-
pared to preoperative RT has been shown to increase
locoregional control of patients with locally advanced* Correspondence: pirus.ghadjar@insel.ch
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distribution, and reproduction in any mediumhead and neck cancer [1]. In addition postoperative RT
increased overall survival (OS) in nodal positive patients
as compared to surgery alone [2]. Furthermore post-
operative cisplatin based chemoradiation is known to in-
crease time to locoregional recurrence as well as OS in
patients with positive resection margins and lymph node
metastasis with extracapsular extension (ECE) [3]. Re-
cently, the development of intensity modulated RT
(IMRT) significantly reduced xerostomia when compared
to 3-dimensional conformal RT in a randomized con-
trolled trial [4,5] and swallowing sparing IMRT has been
described to potentially reduce RT related dysphagia [6].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for IMRT treatment of OCC patients. Having started
IMRT treatments in 2002, we could draw upon own ex-
perience and patient results as well as a small number of
publications [7-13]. We then adapted our institutional
guidelines for treatment and follow-up with a special
focus on target volume definition and dose prescription.
We have now retrospectively analyzed the outcome and
patterns of failure of patients at our center having been
treated accordingly.
Methods
Patient selection
We retrospectively identified all patients with newly
diagnosed OCC with either locally advanced disease
(American Joint Committee on Cancer (AJCC) stage III
or IV) or early stage high-risk disease (positive or close
margins (< 3mm); perineural invasion; lymphovascular
space invasion and synchronous primary tumors) who
underwent postoperative IMRT between December 2006
and July 2010 at our Department of Radiation Oncology,
Inselspital, Bern University Hospital. Patients with a his-
tory of another malignancy within 5 years, histology
other than squamous cell carcinoma, distant metastatic
disease or prior neoadjuvant therapy were excluded.
Patients were staged according to the AJCC 2002 guide-
lines [14]. This study was approved by the local ethics
committee.
Treatment
Prior to start of any treatment, stage of disease, sequence
of treatment and modalities were defined in the weekly
interdisciplinary institutional head-and-neck tumorboard
for all patients.
Surgery
All patients underwent resection of the primary tumor
and an uni- or bilateral modified radical neck dissection
in the Department of Otorhinolaryngology, Head and
Neck Surgery and / or Department of Craniomaxillofa-
cial Surgery, Inselspital Bern, University Hospital. In cN+
patients aim of surgery was complete resection of the pri-
mary tumor and of all cervical metastastic lymph nodes.
The decision to do selective neck dissections in cases
with cN0 or in the contralateral node negative neck was
at the discretion of the head and neck surgeon.
Radiotherapy
Prior to IMRT planning all patients were referred for
dental evaluation and treatment if necessary. For treat-
ment planning a dedicated high-resolution CT scan with
3 mm slices and intravenous contrast was used. Patients
were immobilized in the supine position using a thermo-
plastic mask covering head and shoulders. A bite block /tongue depressor was used to separate upper from lower
jaw, all patients were additionally told to extend their
(remaining) tongue to reach the backside of their lower
jaw incisors and keep the tongue in this position during
treatment if possible. All visible surgical scars were
marked with flexible wires.
It was our policy to contour the resected tumor and
all metastatic lymph nodes in their former location and
full dimension in the planning CT if possible, using all
available information (clinical descriptions, all preopera-
tive imaging modalities, surgical reports). Additional
image fusion of preoperative MRI or PET-CT was per-
formed if deemed useful. Three different risk levels of
clinical target volume (CTV) were defined. CTV72 was
defined as gross tumor either due to early postoperative
tumor progression with an additional isotropic margin
of 1.5 cm and treated to 72 Gy. CTV60-66 was defined
as the former tumor bed (FTB), areas with microscopic-
ally incomplete resection (R1) and all neck levels having
harboured lymph node metastasis with ECE with an
additional isotropic margin of 1.5 cm. In case of
reported intraoperative spillage (tumor and / or meta-
static lymph node rupture) the whole corresponding sur-
gically manipulated area was defined as CTV60-66, e.g.
the complete area of neck dissection [15]. All of CTV60-
66 was treated to 66 Gy except in a few cases of R0 re-
section of the primary tumor with generous margins
(> 5 mm), where the FTB was treated to 60 instead of 66
Gy. CTV54 included the CTV72 or CTV60-66 plus dis-
sected lymph node levels with 1 (pN1) or more meta-
static lymph nodes (pN2b, pN2c) without ECE and the
elective contralateral not dissected neck levels in case of
unilateral neck dissection and was treated to 54 Gy. The
definition of elective nodal target volumes followed the
recommendations proposed by Eisbruch et al. [16]. All
prescribed CTV-margins were anatomically adapted to
account for natural barriers such as thyroid and cricoid
cartilage, hyoid, mandibular or vertebral bone and for
skin and air. The resulting CTVs were finally expanded
to planning target volumes (PTVs) by adding a symmet-
ric 3 mm margin for setup error compensation. In a final
adjustment all PTVs were set back from the skin surface
3–5 mm to allow for dose build-up except where the skin
was deemed to be at risk of harbouring microscopic
tumor e.g. the neck dissection scar in case of tumor spill-
age. Instead of using a skin flap in these cases we tried to
optimize dose build-up by putting more weight on tan-
gential beam directions accepting minor under-dosages.
All planning PTVs were treated sequentially in a
“shrinking-volume” technique with a fractionation of 5
times 2 Gy per week, resulting in two or three treatment
plans per patient. Dose prescription was done to the me-
dian dose D50% of the PTV in accordance with the ICRU
report 83. All treatment plans were contoured and
Table 1 Patient and treatment characteristics (n = 53)
Characteristics n (%)
Age (years)#
≤ 60 25 (47)
> 60 28 (53)
Gender
Female 17 (32)
Male 36 (68)
Karnowsky PS
> 70 42 (79)
≤ 70 11 (21)
Site
Tongue 22 (41)
Floor of mouth 17 (32)
Alveolus and Gingiva 11 (21)
Others* 3 (6)
Tumor classification
pT1 8 (15)
pT2 25 (47)
pT3 5 (10)
pT4 15 (28)
Nodal classification
cN0** 2 (4)
pN0 18 (34)
pN1 10 (19)
pN2 22 (41)
pN3 1 (2)
Grading
Moderate (G2) 37 (70)
Poor (G3) 16 (30)
Resection margins
R0 15 (28)
Close (< 3mm) 25 (47)
R1 13 (25)
Surgery to primary tumor
Wide local excision 9 (17)
Partial glossectomy 18 (34)
Hemiglossectomy 4 (7)
Mandibular resection 4 (7)
Partial maxillectomy 3 (6)
Composite oral cavity resection 15 (29)
Neck dissection##
None 2 (4)
Ipsilateral 28 (53)
Bilateral 23 (43)
Table 1 Patient and treatment characteristics (n = 53)
(Continued)
Gastrostomy tube
None 28 (53)
Used 25 (47)
Abbreviations: PS performance status; # median 60 years (range, 40–88 years);
* buccal mucosa n=2 and hard palate n=1; **Two patients (4%) did not
undergo a neck dissection; ## Of the 51 patients who underwent a neck
dissection a median of 44 nodes (range, 14–101 nodes) were removed.
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Figure 1 Locoregional recurrence-free survival (LRRFS) (A),
distant metastasis-free survival (DMFS) (B) and overall survival
(OS) (C).
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Medical Systems, Palo Alto, CA).Concomitant systemic therapy
The standard concomitant therapy consisted of cisplatin
100mg/m2 day1 in three week intervals for all patients.
Patients not deemed fit for cisplatin chemotherapy be-
cause of pre-existing co-morbidities or poor overall per-
formance status were occasionally evaluated for
treatment with either carboplatin or the monoclonal
antibody cetuximab in an individual therapeutic ap-
proach by the responsible medical oncologist knowing
that there is until present no sufficient data to prove the
benefit of this treatment.Assessments and evaluations
After RT all patients underwent follow-up visits on a regular
basis. These visits were scheduled every 3 months for the
first 2 years, twice a year until the 5th year and yearly there-
after. For this study the follow-up information closeout date
was September 2011. Eight to twelve weeks after the end of
treatment a post-therapy baseline CT or MRI was
performed.
Time-to-event endpoints were calculated from end of
RT until the date of event. Patients not experiencing an
event were censored at the date of the last follow-up visit.Table 2 Treatment outcome analysis
Factor Associated level Cox regression a
LRRFS
Univariate analysis
Age (years) >60 1.31 (0.42, 4.13) (0
Sex Male 0.92 (0.27, 3.07) (0
KPS ≤70 1.20 (0.32, 4.44) (0
T-classification pT3-4 1.73 (0.56, 5.37) (0
N-classification pN2-3 4.71 (1.27, 17.45) (
AJCC stage IV 4.43 (0.97, 20.27) (
Grading G3 1.82 (0.58, 5.73) (0
Resection margins R1 0.65 (0.14, 2.98) (0
ECE positive LN yes 2.29 (0.74, 7.14) (0
Chemotherapy* yes 0.56 (0.18, 1.75) (0
Flap reconstruction yes 1.92 (0.58, 6.42) (0
Bilateral ND yes 0.38 (0.10, 1.40) (0
Gastrostomy tube yes 1.68 (0.53, 5.30) (0
Time OP to RT > 6 weeks 0.59 (0.19, 1.89) (0
Multivariate analysis
N-classification pN2-3 4.71 (1.27, 17.45) (
AJCC stage IV 1.68 (0.15, 18.51) (
Abbreviations: LRRFS Locoregional recurrence-free survival, DMFS Distant metastasis
score, ECE extracapsular extention, LN lymph node, n.a. not applicable, ND neck disToxicities were graded according to the National Can-
cer Institute (NCI) Common Terminology Criteria for
adverse events (CTCAE) version 3.0. The symptoms
pain, dermatitis, mucositis, dysphagia, xerostomia and
osteonecrosis were assessed. Acute toxicity was defined
as complications during RT and until 3 months after end
of RT; late toxicity as complications occurring thereafter.
Analysis of recurrences
The recurrent or persistent tumor volume as defined by all
available diagnostic images, was used to categorize the
recurrences as “in-volume”, if >95% of the recurrent locor-
egional tumor volume was within the corresponding
CTV54, CTV60-66 or CTV72; “marginal”, if 20–95% was
within the CTV54, CTV60-66 or CTV72; or “out-volume”,
if <20% of the recurrent tumor volume was within the re-
spective CTV, as previously described [17,18]. The relation
of all recurrences to both CTVs was assessed sequentially.
Statistical considerations
The primary endpoint was locoregional recurrence-free sur-
vival (LRRFS). Secondary endpoints included distant
metastasis-free survival (DMFS), OS, acute and late toxicity.
Late toxicity at last follow-up visit was also assessed to de-
termine whether the late toxicity persisted or was transient.
Time-to-event endpoints were estimated using the Kaplan
Meier method. Univariate and multivariate analyses werenalysis hazard ratio (95% CI) (p-value)
DMFS OS
.64) 1.44 (0.24, 8.62) (0.69) 2.46 (0.65, 9.28) (0.18)
.89) 0.75 (0.12, 4.48) (0.75) 1.81 (0.39, 8.44) (0.45)
.79) 0.94 (0.11, 8.46) (0.96) 0.74 (0.16, 3.42) (0.70)
.34) 2.44 (0.41, 14.58) (0.33) 1.43 (0.44, 4.70) (0.55)
0.02) 114.6 (0.06, >1000) (0.22) 4.65 (1.23, 17.63) (0.02)
0.05) 56.7 (0.04, >1000) (0.27) 4.13 (0.90, 19.10) (0.07)
.31) 3.4 (0.57, 20.4) (0.18) 0.89 (0.24, 3.40) (0.87)
.58) 0.78 (0.09, 6.96) (0.82) 1.73 (0.50, 5.93) (0.38)
.15) 3.54 (0.58, 21.4) (0.17) 2.19 (0.66, 7.27) (0.20)
.32) 1.15 (0.19, 6.89) (0.88) 0.44 (0.13, 1.50) (0.20)
.29) 59.4 (0.04, >1000) (0.27) 2.48 (0.66, 9.35) (0.16)
.15) 0.74 (0.12, 4.46) (0.75) 0.59 (0.17, 2.01) (0.40)
.38) 1.70 (0.28, 10.17) (0.56) 1.03 (0.31, 3.38) (0.96)
.38) 0.73 (0.12, 4.37) (0.73) 0.68 (0.19, 2.35) (0.54)
0.02) n.a. 4.65 (1.23, 17.63) (0.02)
0.67) n.a. 1.53 (0.14, 16.94) (0.73)
-free survival, OS Overall survival, OP surgery, KPS Karnowsky performance
section, *including treatment with cetuximab.
Table 3 Localization and pattern of tumor recurrences in relation to the clinical target volumes
Site of
Primary
T N R ECE Flap Systemic
therapy
Time to
recurrence
(yrs)
Compartment
of recurrence
Localization and pattern of
recurrence
Relation of
recurrence
to CTV 54
Relation of
recurrence
to CTV60-66
Floor of
mouth
4 2b c Yes Yes Yes 0.2 Local Outside FTB, not involving flap,
multifocal
Marginal Marginal
0.8 Distant Lung n.a n.a
Floor of
mouth
1 2b c No No Yes 3.1 Local Outside FTB, ipsilateral dorsal edge
of tongue, unifocal
Marginal Marginal
Floor of
mouth
4 2b c Yes Yes Yes 0.7 Local Within FTB and flap, multifocal In Marginal
0.7 Distant Lung n.a n.a
Lower
alveolar ridge
4 2b 1 Yes Yes No 0.3 Local Within FTB and flap, multifocal
0.3 Regional Ipsilateral neck, multifocal
In In
0.4 Distant Lung, Pleura, Skin, Liver n.a n.a
Tongue 2 2b c No No No 0.5 Local Within FTB, unifocal
In Marginal0.5 Regional Bilateral neck (ipsilateral bulky),
multifocal
Tongue 2 2b 0 No Yes No 0.2 Local Within FTB and flap, unifocal
0.2 Regional Bilateral neck, multifocal
In Marginal
0.2 Distant Pleura n.a n.a
Buccal
mucosa
2 2b 1 Yes Yes Yes 0.1 Local Within bed of surgical resection and
flap, multifocal Marginal Marginal
0.1 Regional Contralateral neck, unifocal
Tongue 3 2b 0 Yes Yes No 0.7 Local Within FTB and flap, multifocal
In Marginal
0.7 Regional Contralateral neck, unifocal
Tongue 2 0 0 No No No 0.7 Local Within FTB, unifocal
Marginal Marginal
0.7 Regional Contralateral neck, multifocal
Tongue 3 2c c Yes Yes Yes 0.7 Regional Contralateral neck, unifocal In In*
Tongue 1 0 c No No No 1.3 Regional Contralateral neck, unifocal Out Out
Lower
alveolar
ridge, edge
of tongue
4 0 0 No Yes No 0.5 Regional Outside FTB, not involving flap,
extending to ipsilateral base of skull
and Fossa infratemporalis, unifocal
Out Out
Abbreviations: T tumor classification, N nodal classification, R resection margin, c close (< 3 mm), CTV clinical target volume, n.a. not applicable;
FTB former tumor bed, CTV clinical target volume, *this patient was one of the two patients who received a total dose of 72 Gy, the regional
recurrence was inside the CTV72Gy.
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backward selection method (criterion for removal: p ≥ 0.05).
To be assessed in the multivariate analysis, a variable had to
be significant (p ≤ 0.1) in the univariate analysis. Categor-
ical variables were summarized using absolute and relative
frequencies; continuous variables by descriptive statistics.
P-values were two-sided, not adjusted for multiple testing,
and considered significant if < 0.05. The data were ana-
lyzed in SPSS (SPSS Inc., Chicago, IL, version 19.0) and
SAS (Statistical Analysis Systems Institute Inc, version
9.2).
Results
Patient and treatment characteristics
In total 53 patients were retrospectively analyzed. Seven
and thirty patients had AJCC stage III (13%) or IV(57%), in the remaining 16 patients with AJCC stage I/II
(30%), the following risk factors were present: positive
margins (n=2), close margins (n=9), perineural invasion
(n=3), lymphovascular space invasion (n=2) and 1 pa-
tient had 2 synchronous primary tumors (buccal mucosa
and tongue). Pre-treatment staging of the head and neck
was performed by either CT (n=33), MRI (n=12) or both
(n=8). Prior to treatment, a PET-CT scan was used on 9
patients (17%). A total of 17 patients were ECE positive.
Twenty-nine patients (55%) underwent soft tissue recon-
struction using either a local musculocutaneous pedicled
flap (n=17), regional musculocutaneous pedicled flap
(n=6) or free flap (n=6). ECE was detected in 11 flap re-
construction cases. Further patient and treatment char-
acteristics are summarized in Table 1. Median time
between surgery and RT was 6.7 (range, 3–17) weeks.
Table 4 Pre-treatment morbidity and acute and late
toxicity
Pre-Tx Acute† Late‡ Last late§
Toxicity Grade n (%) n (%) n (%) n (%)
Pain 0 31 (59) 1 (2) 42 (80) 47 (89)
1 16 (30) 12 (23) 4 (7) 0
2 6 (11) 32 (60) 5 (9) 5 (9)
3 - 8 (15) 2 (4) 1 (2)
Dermatitis 0 53 (100) - 51 (96) 53 (100)
1 - 14 (26) 1 (2) -
2 - 30 (57) 1 (2) -
3 - 9 (17) - -
Mucositis 0 53 (100) - 50 (94) 53 (100)
1 - 7 (13) 1 (2) -
2 - 27 (51) 1 (2) -
3 - 19 (36) 1 (2) -
Dysphagia 0 25 (47) 5 (9) 28 (53) 35 (66)
1 4 (7) 5 (9) 4 (7) 7 (14)
2 17 (32) 25 (48) 16 (31) 6 (11)
3 7 (14) 18 (34) 5 (9) 5 (9)
Xerostomia 0 53 (100) 37 (70) 34 (64) 40 (75)
1 - 13 (24) 15 (29) 10 (19)
2 - 3 (6) 4 (7) 3 (6)
3 - - - -
Osteonecrosis 0 53 (100) 52 (98) 51 (96) 53 (100)
1 - - - -
2 - 1 (2) 2 (4) -
Highest* 0 19 (36) - 18 (34) 30 (57)
1 7 (13) 4 (7) 11 (21) 11 (21)
2 20 (38) 14 (27) 18 (34) 7 (13)
3 7 (13) 35 (66) 6 (11) 5 (9)
Abbreviations: Pre-Tx pre-treatment morbidity; * The highest morbidity/toxicity
in a patient was counted as a single event; † During therapy and until 3
months after completion; ‡ maximal late toxicity > 3 months after completion
of therapy; § Incidence of late toxicity at last follow-up visit. Percentages were
rounded to reach 100% for every symptom.
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patients received 72 Gy as there was evidence of macro-
scopic neck metastasis during treatment planning.
Twenty-five patients (47%) underwent concomitant
chemotherapy (cisplatin n=23, carboplatin n=2). The
median number of chemotherapy cycles was 3 (range,
2–3). Four patients (8%) underwent treatment with the
monoclonal antibody cetuximab. The median follow-up
was 2.3 (range, 1.1–4.6) years for the surviving patients.
Locoregional recurrence
At the time of analysis, 9 local recurrences and 9 re-
gional recurrences were observed in 12 patients. Ofthose patients, 3 had only local recurrence, three had
only regional recurrence and 6 had both. The median
time to locoregional recurrence was not reached. The 2-
and 3-year LRRFS estimates were both 79% (Figure 1A).
In a multivariate Cox proportional hazards model, N-
classification > N1 remained a significant prognostic fac-
tor for LRRFS (hazard ratio (HR): 4.7; 95% Confidence
interval (CI): 1.3–17.4; p=0.02)) (Table 2).
The patterns of failure analysis revealed that 8 out of
12 locoregional recurrences showed an unusual multi-
focal pattern of recurrence, five of these patients had a
flap reconstruction and ECE. Six of the total 12 locore-
gional recurrences occurred within the CTV54; 10 of
the 12 marginally or outside of the CTV60-66 or
CTV72 (Table 3).
Distant metastasis
At the time of analysis 5 patients had developed distant
metastasis, located in the lung, pleura, skin (n=1), bone
and soft tissue (n=1), pleura (n=1) or lung only (n=2).
All patients who developed metastasis had also either
local or regional recurrence. The 2- and 3-year DMFS
estimates were both 90% (Figure 1B). No clinical or
pathological variable was found to be associated with
distant metastasis (Table 2).
Overall survival
Eleven patients (21%) died during follow-up; 9 due to cancer
progression (cancer specific deaths), one patient due to
cachexia and the other due to cardiac failure. The 2- and 3-
year OS estimates were 83% and 73% (Figure 1C), and the
respective cancer-specific survival rates were 85% and 82%.
In a multivariate Cox proportional hazards model using
backward selection, N-classification > N1 was the only sig-
nificant prognostic factor for OS (HR: 4.6, 95% CI: 1.2–17.6;
p=0.02) (Table 2).
Pre-RT morbidity and acute and late toxicity
After surgery and prior to RT, pre-RT morbidity was
determined (Table 4). Six patients (11%) were identified
with pre-RT grade 2 pain, 17 (32%) had pre-RT grade 2
dysphagia and 7 (14%) had pre-RT grade 3 dysphagia.
The highest grade of acute toxicity was: grade 2 in 14
patients (27%); grade 3 in 35 patients (66%). No toxicity
related interruptions of RT occurred. The highest grade
of late toxicity was: grade 2 in 18 patients (34%); grade 3
in 6 patients (11%). At the last follow-up visit the highest
grade of late toxicity was: grade 2 in 7 patients (13%);
grade 3 in 5 patients (9%).
Discussion
Since 2007 the outcome and patterns of failure of
postoperative IMRT for OCC have been described by
others [7-13].
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publications in regard to median age, TNM and AJCC
stage, median follow-up and time interval between surgery
and RT. Our CTV definitions and dose prescriptions are
almost identical to those reported by Sher et al. [13], the
relevant difference being that we prescribed 54 Gy to dis-
sected and involved lymph node levels in the absence of
ECE instead of 60 Gy. The CTV definitions and dose pre-
scriptions of the remaining publications vary considerably
in detail, especially when describing high-risk CTV. The
FTB is uniformly assigned doses around 70 Gy in case of
gross residual disease and 66 Gy in R1 except by Chen
et al. [10] who applied a median dose of 61.1 Gy. The pre-
scription range for dissected lymph node levels containing
metastatic nodes is 60–66 Gy in the presence of ECE and
54–60 Gy without ECE, elective (low neck and contralat-
eral) lymph node levels are prescribed 46.8 to 56 Gy.
The 2- and 3-year LRRFS, DMFS and OS estimates
observed in our study compare well with previously pub-
lished reports (Table 5). N-classification was the only
significant prognostic factor for both LRRFS and OS in
multivariate analysis, consistent with the findings of
Chen et al. [10]. Others reported ECE or positive mar-
gins and total treatment time as significant [8,11].
Our patterns of failure analysis revealed an unusual
multifocal recurrence pattern in 8 out of 12 patients in-
volving areas of tumor resection, neck dissection and flap
reconstruction making a precise allocation into categories
of “local” or “regional” recurrence quite impossible. In re-
lation to CTV54 and CTV60-66 or CTV72 coverage the
recurrences showed an unexpected variety (Table 3) with
“marginal” and “out” volume recurrences in relation to
both CTVs. Four patients had multifocal recurrences com-
pletely covered by CTV54; therefore they could have been
reported as “in” volume recurrences, but because less thanTable 5 Treatment details and results of retrospective reports
Report
(reference)
n Median age
(years)
Stage (%) Median Time from
surgery to RT (wee
Studer (7) 28 61* III (14) nr
IV (54)
Chen (10) 22 50 III (27) nr
IV (73)
Gomez (9) 35 nr III (26) 7
IV (54)
Daly (11) 30 61 III (23) 6
IV (53)
Sher (13) 30 nr nr 7
Present analysis 53 60 III (13) 7
IV (57)
Abbreviations: LRFS local recurrence-free survival, LRRFS locoregional recurrence-fre
overall survival, RT radiotherapy,*mean age; #2 year actuarial estimates; three year a95% of all recurrent tumor masses were covered by
CTV66 we additionally report them as “marginal” to
CTV66. One of these patients for example recurred in the
FTB and in the ipsilateral dissected and contralateral not
dissected neck with 6 volumes of tumor all within CTV54,
whereas 2 recurrences in the contralateral Level I were
not covered by CTV60-66. Thus, in 10 out of 12 patients
the locoregional recurrence occurred marginally or out-
side of the high-risk target volumes. A similar pattern of
failure is reported by Yao et al. [8] with 4 out of 9 locore-
gional failures being multifocal and 3 of these 4 failing in
both CTV60 and CTV64-66, though neither aspect is
discussed in the paper. Daly et al. [11] give a detailed de-
scription of 13 locoregional treatment failures after post-
operative RT, with only 3 failures “entirely within high-risk
PTV60 or PTV66” and 2 multifocal failures not assessed
in respect to PTV coverage at all, meaning the remaining
8 failures were at least “marginal” or “out” of the high-risk
volume. The remaining publications however [7,9,10,13]
do not quantify dose coverage of their failures and do not
describe multifocal recurrences. We therefore propose to
describe recurrences as unifocal or multifocal as this is an
important predictor for surgical salvage [19].
Eight out of our 12 recurrences had extensive surgery
requiring flap reconstruction, and 5 of these failed multi-
focally involving the flap reconstruction. All of these 5
patients had ECE, and there might have been tumor cell
spillage during surgery [15]. Finding no proposals for
target volume delineation regarding flap reconstructions
in an extensive literature search we have now started to
fully include flap reconstructions in the CTV54 in case
of synchronous ECE.
Another one of our patients with extensive perineural
invasion failed “out” of treatment volume having recurred
in the ipsilateral infratemporal fossa with tumor cellswith postoperative IMRT in oral cavity cancer
ks)
Systemic
therapy (%)
Median
follow-up
(mts)
LRFS (%) LRRFS (%) OS (%)
86 19 92# nr 83#
9 44 nr 64** 67¶
29 28 89** 77 74
60 38 67 53 60
nr nr nr 91# 85#
55 28 83 79 73
e survival, mts months, n eligible patients, nr not reported separately, OS
ctuarial estimates; **Crude rate.
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type of recurrence already described in detail [8].
Concerning side effects, the acute toxicity grading was
2 in 27% of patients and 3 for 66%. The late toxicity
grading was 2 in 34% of patients and 3 in 11%. The use
of different methods for assessing toxicities and the var-
iety of symptoms assessed makes it difficult to compare
results across trials. However, our data do compare fa-
vorably with the toxicity rates outlined by Sher et al.
assessed by CTCAE version 4.0. [13]. It is important to
note that we did not observe acute toxicity related treat-
ment interruptions. When late toxicity was assessed at
the last follow-up visit, the rates were below the pre-RT
morbidity symptoms. This could be partly due to
increased pain medication, use of gastrostomy tubes and
other medical interventions as well as full recovery from
surgery. Our study is limited due to its retrospective na-
ture. Despite this limitation it appears that LRRFS after
postoperative IMRT is promising with acceptable acute
and late toxicity rates.
Conclusion
Postoperative IMRT of locally advanced or high-risk
OCC was associated with satisfying LRRFS. Acute and
late toxicity rates were acceptable. Our patterns of fail-
ure analysis emphasizes the need to improve high-risk
CTV target volume definition, as the majority of our
locoregional recurrences occurred marginal to or outside
of the high-risk CTV. Having seen unusual multifocal
recurrences in 5 of 8 patients with both ECE and flap re-
construction, we propose to fully include the volume of
flap reconstruction in the elective CTV in this scenario.
Further improvement of high-risk CTV definition might
generally transfer into better LRRFS.
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